Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MDNRA obtains peptide IP for RNAi

This article was originally published in Scrip

Executive Summary

MDRNA plans to improve the delivery of RNAi therapeutics after signing an exclusive licence agreement to intellectual property from the University of Michigan that covers cationic peptides. Terms of the agreement were not disclosed. Dr Michael Houston, vice-president of chemistry and formulations, says that the university's peptides have "the potential of being critical components of RNAi-based therapeutic formulations". The company is using its proprietary platform for creating novel lipids from amino acids, DiLA, to enhance gene expression knockdown. The peptides covered by the university's IP can form stable siRNA nanoparticle complexes, thereby protecting the siRNA while increasing the efficiency and efficacy of formulations. Results to date have shown enhanced knockdown of target proteins in vivo and improved delivery efficiency, says MDRNA. The company has recently restructured and changed its focus away from intranasal delivery towards RNAi (Scrip Online, August 8th, 2008).

You may also be interested in...

Innovation not M&A to drive Bayer growth in LatAm

Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.

2010 Scrip 100 - Is Anvisa a friend of innovators?

A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.

Elan raises $1.5 billion

Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts